Top news of November: Semaglutide CV outcomes, treating statin intolerance and more
Click Here to Manage Email Alerts
Healio and Cardiology Today have compiled a list of the most-read news in cardiology of November 2023.
Readers were most interested in the results of the SELECT trial of semaglutide in patients with CVD and obesity; strategies to address statin intolerance; AI that evaluates coronary inflammation to assess CV risk events in patients undergoing coronary CTA; and more.
Image: Adobe Stock
Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT
In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes. Read more
‘We have options’: New strategies for treating statin intolerance
There are many options for statin-intolerant patients, including alternative dosing schedules and nonstatin therapies. Check out part 3 of a three-part Healio Exclusive series on developments and challenges in heart transplantation. Read more
AI-enabled technology independently predicts cardiac events based on coronary inflammation
An artificial intelligence-based technology that evaluates coronary inflammation predicted risk for cardiac events in patients undergoing coronary CTA, according to new study data. Read more
Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction
Recaticimab, a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy, a speaker reported. Read more
Injectable antihypertensive drug lowers blood pressure for up to 6 months
Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial. Read more
New atrial fibrillation guideline highlights early rhythm control, prevention strategies
An updated guideline on the prevention and management of atrial fibrillation includes a new staging system to emphasize disease progression, along with updated recommendations for catheter ablation and left atrial appendage occlusion. Read more
Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition
A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient. Read more
Physical activity and atrial fibrillation: Where’s the balance?
In this editorial, experts summarize the recently published a review in the Journal of Cardiovascular Development and Disease that evaluated the relationship between physical activity and AF. Read more
Regular marijuana use linked to risk for HF, major adverse heart, brain events
Two observational studies presented at the American Heart Association Scientific Sessions linked regular marijuana use to elevated risk for HF and elevated risk for major adverse cardiac and cerebrovascular events. Read more
Pharmacology Consult: GLP-1 receptor agonists for weight loss management
GLP-1 receptor agonists are associated with significant weight loss in patients with obesity. In this editorial, experts review a strategy for minimizing adverse events from these drugs. Read more
Collapse
Healio Coverage
Click Here to Manage Email Alerts